On September 14, BIOCYTOGEN-B rose 6.15% in regular trading to HKD 59.55, with turnover of HKD 78.744 million, rebounding after consecutive sessions of pullback.

The rally was underpinned by strong H1 earnings and a recent licensing collaboration. The company reported H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.29% to RMB 241 million, marking the fifth consecutive profitable quarter. Preclinical products and services revenue reached RMB 723.5 million, up 57.9%, with innovative animal model sales growing 62.4% at an 82.3% gross margin. Antibody discovery revenue rose 33.8% to RMB 217.9 million, maintaining a 92.8% gross margin.

Additionally, the company recently signed a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule generated by its proprietary RenNano platform, targeting neurological drug development. The H1 earnings briefing disclosed over 105 new cooperation agreements signed during the period, with further acceleration expected in the second half.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)